Cellectis signed CRISPR/Cas9 licensing deal with University of Minnesota

Cellectis Plant Sciences recently announced it has signed an exclusive licensing agreement with the University of Minnesota, granting the firm worldwide rights to patents covering the use of CRISPR/Cas9 technology in plants.

The technology, developed for genome engineering in plants by University of Minnesota Professor Dan Voytas, strengthens Cellectis’ gene editing property rights, the firm said in a statement. Cellectis also has rights to use meganuclease and transcription activator-like effector nuclease-based gene editing technologies.

Applying CRISPR/Cas9 gene editing in plants could help scientists develop valuable crops, the firm said in a statement.
Financial and other details of the agreement were not disclosed.